Состав:
Страница осмотрена фармацевтом Федорченко Ольгой Валерьевной Последнее обновление 16.05.2022
Внимание! Информация на странице предназначена только для медицинских работников! Информация собрана в открытых источниках и может содержать значимые ошибки! Будьте внимательны и перепроверяйте всю информацию с этой страницы!
Топ 20 лекарств с такими-же компонентами:
Terfenadine is indicated for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation.
Clinical studies conducted to date have not demonstrated effectiveness of Terfenadine in the common cold.
Terfenadine was withdrawn from the U.S. market in 1998.
Terfenadine is an antihistamine. Antihistamines prevent sneezing, runny nose, itching and watering of the eyes, and other allergic symptoms.
Terfenadine is used to treat allergies, hives (urticaria), and other allergic inflammatory conditions.
Terfenadine may also be used for purposes other than those listed in this medication guide.
Одна таблетка (60 мг) два раза в день для взрослых и педиатрических пациентов в возрасте 12 лет и старше.
ИСПОЛЬЗОВАНИЕ ДОЗ В ОТНОШЕНИИ 60 МГ Б.И.Д. НЕ РЕКОМЕНДУЕТСЯ ПОТОМУ ЧТО УВЕЛИЧЕННЫЙ ПОТЕНЦИАЛ ДЛЯ QT ИНТЕРВАЛЬНЫХ ПРОДВИЖЕНИЙ И ПОКРЫТИЯ КАРДИАКА, СОДЕРЖАНИЕ Терфенадина У ПАЦИЕНТОВ С ЗНАЧИТЕЛЬНЫМ ГЕПАТИЧЕСКИМ ДИСУНКЦИНОМ И У ПАЦИЕНТОВ.
Как поставляется
Удален с рынка 1998
Таблетки по 60 мг во флаконах по 100.
Таблетки по 60 мг во флаконах по 500.
Таблетки круглые, белые и с тиснением «Терфенадин (терфенадин (удален с рынка 1998))». Хранить таблетки при контролируемой комнатной температуре (59-86 ° F) (15-30 ° C). Защищать от воздействия температур выше 104 ° F (40 ° C) и влаги.
Смотрите также:
Какую самую важную информацию я должен знать о терфенадине?
СОВМЕСТНОЕ УПРАВЛЕНИЕ Терфенадином КЕТОКОНАЗОЛОМ (NIZORAL) ИЛИ ИТРАКОНАЗОЛЬ (SPORONOX) ПРОТИВОСТОЯНИЕ. Терфенадин также противостоит пациентам с государствами болезни или другими сопутствующими средствами, известными своему метаболизму, ВКЛЮЧАЯ ЗНАЧИТЕЛЬНУЮ ГЕПАТИЧЕСКУЮ ДИСФУНКЦИЮ, И КОНЦУРРЕНТНОЕ ИСПОЛЬЗОВАНИЕ КЛАРИТРОМИцина, ERYTROMYCIN, ИЛИ ТРОЛАНДОМИЦИН. QT ПРОДОНГАЦИЯ БЫЛА ДЕМОНСТРИРОВАНА У НЕКОТОРЫХ ПАЦИЕНТОВ, ПРИНИМАЮЩИХ Терфенадин В ЭТИХ УСТАНОВКАХ, И РЕДКОЕ СЛУЧАЕ СЕРЬЕЗНЫХ КАРДИОВАЗУЛЬТАТЫХ СОБЫТИЙ, ВКЛЮЧАЯ СМЕРТЬ, КАРДИАК АРРЕСТ, И ТОРСАДЫ ДЕ ТОЧКИ, ОТЧЕТЫ В ЭТИХ ПАЦИЕНТНЫХ НАСЕЛЕНИЯХ .
Терфенадин противопоказан пациентам с известной гиперчувствительностью к терфенадину или любому из его ингредиентов.
Терфенадин используется для лечения аллергических состояний, таких как воспаление глаз и носа, крапивница, зуд и аллергическое чихание. Однако этот препарат был снят с рынка из-за риска сердечных проблем.
See also:
What other drugs will affect Terfenadine?
Ketoconazole
Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of Terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. death, cardiac arrest, and ventricular arrhythmia including torsades de pointes. Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of Terfenadine, resulting in elevated plasma Terfenadine levels. Presence of unchanged Terfenadine is associated with statistically significant prolongation of the QT and QTc intervals.Concomitant administration of ketoconazole and Terfenadine is contraindicated.
Itraconazole
Torsades de pointes and elevated parent Terfenadine levels have been reported during concomitant use of Terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. One death has also been reported from foreign post- marketing sources. Concomitant administration of itraconazole and Terfenadine is contraindicated.
Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with Terfenadine is not recommended pending full examination of potential interactions.
Macrolides
Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on Terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. Although erythromycin measurably decreases the clearance of the Terfenadine acid metabolite, its influence on Terfenadine plasma levels is still under investigation. A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin.
Concomitant administration of Terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of Terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. Studies to evaluate potential interactions of Terfenadine with azithromycin are in progress.
See also:
What are the possible side effects of Terfenadine?
Cardiovascular Adverse Events
Rare reports of severe cardiovascular adverse effects have been received which include ventricular tachyarrhythmias (torsades de pointes, ventricular tachycardia, ventricular fibrillation, and cardiac arrest), hypotension, palpitations, syncope, and dizziness. Rare reports of deaths resulting from ventricular tachyarrhythmias have been received. Hypotension, palpitations, syncope, and dizziness could reflect undetected ventricular arrhythmia. IN SOME PATIENTS, DEATH, CARDIAC ARREST, OR TORSADES DE POINTES HAVE BEEN PRECEDED BY EPISODES OF SYNCOPE.. Rare reports of serious cardiovascular adverse events have been received, some involving QT prolongation and torsades de pointes, in apparently normal individuals without identifiable risk factors. There is not conclusive evidence of causal relationship of these events with Terfenadine. Although in rare cases there was measurable plasma Terfenadine, the implications of this finding with respect to the variability of Terfenadine metabolism in the normal population cannot be assessed without further study. In controlled clinical trials in otherwise normal patients with rhinitis, small increases in QTc interval were observed at doses of 60 mg b.i.d. In studies of 300 mg b.i.d. a mean increase in QTc of 10% (range -4% to +30%)(mean increase of 46 msec) was observed.
General Adverse Events
Experience from clinical studies, including both controlled and uncontrolled studies involving more than 2,400 patients who received Terfenadine, provides information on adverse experience incidence for periods of a few days up to six months. The usual dose in these studies was 60 mg twice daily, but in a small number of patients, the dose was as low as 20 mg twice a day, or as high as 600 mg daily.
In controlled clinical studies using the recommended dose of 60 mg b.i.d., the incidence of reported adverse effects in patients receiving Terfenadine was similar to that reported in patients receiving placebo..
TABLE 1 - ADVERSE EVENTS REPORTED IN CLINICAL STUDIES
In addition to the more frequent side effects reported in clinical trials, adverse effects have been reported at a lower incidence in clinical trials and/or spontaneously during marketing of Terfenadine that warrant listing as possibly associated with drug administration. These include: alopecia (hair loss or thinning), anaphylaxis, angioedema, bronchospasm, confusion, depression, galactorrhea, insomnia, menstrual disorder (including dysmenorrhea), musculoskeletal symptoms, nightmares, paresthesia, photosensitivity, rapid flare of psoriasis, seizures, sinus tachycardia, sweating, thrombocytopenia, tremor, urinary frequency and visual disturbances.
In clinical trials, severe instances of mild, or in one case, moderate transaminase elevations were seen in patients receiving Terfenadine. Mild elevations were also seen in placebo treated patients. Marketing experiences include isolated reports of jaundice, cholestatic hepatitis, and hepatitis. In most cases available information is incomplete.
В США терфенадин был заменен фексофенадином в 1990-х годах из-за риска сердечной аритмии, вызванной удлинением интервала QT.